Vyepti (eptinezumab-jjmr) is a migraine preventive medication that works by targeting the calcitonin gene-related peptide (CGRP) pathway [1].
How does Vyepti stop migraines?
Vyepti is an antibody that binds to the CGRP ligand, a molecule implicated in migraine pathophysiology. By blocking the CGRP ligand, Vyepti prevents CGRP from binding to its receptors, thereby inhibiting the cascade of events that can lead to migraine attacks [1]. CGRP is released during a migraine and is thought to cause inflammation and pain by dilating blood vessels in the brain and transmitting pain signals [2].
What is CGRP and why is it important for migraines?
Calcitonin gene-related peptide (CGRP) is a neuropeptide found throughout the nervous system, including in the trigeminal nerve, which plays a significant role in migraine. During a migraine, CGRP is released, leading to vasodilation and neurogenic inflammation, contributing to the throbbing pain characteristic of migraines [1][3]. Medications that target CGRP, like Vyepti, aim to interrupt this process to prevent or reduce migraine frequency [3].
When does Vyepti patent expire?
Information regarding the specific patent expiration dates for Vyepti is available through resources like DrugPatentWatch.com [4]. Patent exclusivity for Vyepti would determine when generic versions could potentially enter the market.
How does Vyepti compare to other CGRP inhibitors?
Vyepti is one of several CGRP-targeting therapies available for migraine prevention. Unlike some oral CGRP receptor antagonists, Vyepti is an intravenous infusion that targets the CGRP ligand. Other CGRP inhibitors include monoclonal antibodies administered subcutaneously (e.g., erenumab, fremanezumab, galcanezumab) and oral small molecules that block the CGRP receptor [3]. The choice of therapy often depends on individual patient needs and physician recommendations.
What are the approved uses for Vyepti?
Vyepti is indicated for the preventive treatment of migraine in adults [1].
How is Vyepti administered?
Vyepti is administered as an intravenous infusion every 12 weeks [1].
---
Sources:
[1] https://www.vantocan.com/hcp/vyepti/mechanism-of-action
[2] https://www.vyepti.com/migraine-treatment/how-vyepti-works/
[3] https://www.drugpatentwatch.com/blog/cgrp-inhibitors-what-you-need-to-know/
[4] https://www.drugpatentwatch.com/